A5063819659- Poxvirus research and outbreaks
- Bacillus and Francisella bacterial research
- Immunotherapy and Immune Responses
- Herpesvirus Infections and Treatments
- Prostate Cancer Treatment and Research
- Respiratory viral infections research
- Animal Virus Infections Studies
- Viral Infections and Immunology Research
- Multiple Myeloma Research and Treatments
- Meta-analysis and systematic reviews
- Zoonotic diseases and public health
- Vector-borne infectious diseases
- Emergency and Acute Care Studies
- Sepsis Diagnosis and Treatment
- Plant Virus Research Studies
- Radiopharmaceutical Chemistry and Applications
- Empathy and Medical Education
- Patient-Provider Communication in Healthcare
- Infant Development and Preterm Care
- Economic and Financial Impacts of Cancer
- PARP inhibition in cancer therapy
- Complementary and Alternative Medicine Studies
- Intensive Care Unit Cognitive Disorders
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Health Systems, Economic Evaluations, Quality of Life
Bavarian Nordic (United States)
2018-2024
Vall d'Hebron Hospital Universitari
2019
National Institutes of Health
2019
Aalborg University
2019
London Health Sciences Centre
1998-2000
Victoria Hospital
1998
Research Network (United States)
1998
Canadian Lung Association
1998
PROSTVAC, a viral vector-based immunotherapy, prolonged median overall survival (OS) by 8.5 months versus placebo in metastatic castration-resistant prostate cancer phase II study. This III study further investigated those findings.Patients were randomly assigned to PROSTVAC (Arm V; n = 432), plus granulocyte-macrophage colony-stimulating factor VG; or P; 433), stratified prostate-specific antigen (less than 50 ng/mL v more) and lactate dehydrogenase 200 U/L more). Primary end point was OS....
Objective To determine the clinical features and outcomes of patients readmitted to intensive care unit (ICU) during same hospital stay causes for these readmissions. Design Multicenter, cohort study. Setting Three ICUs from two teaching hospitals four community hospitals. Patients All ICU admissions were collected prospectively a registry database in seven ICUs. We retrospectively analyzed between January 1, 1995 February 29, 1996. Interventions None. Measurements Main Results During study...
Although modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccination is approved for smallpox and monkeypox prevention, immunological persistence booster effects remain undescribed.Participants naive to were randomized 1 dose MVA-BN (1×MVA, n = 181), 2 doses (2×MVA, 183), or placebo (n 181). Participants with previous received (HSPX, 200). Subsets of the formerly groups (approximately 75 each) an years later.Neutralizing antibody (nAb) geometric mean titers (GMTs) increased from 1.1...
Modified Vaccinia Ankara Bavarian Nordic (MVA-BN) as a smallpox and mpox vaccine has been approved in its liquid-frozen (LF) formulation the US, Canada, EU. A freeze-dried (FD) may offer additional benefits, such longer shelf life reduced dependence on cold chain storage transport. In phase 2 clinical trial, 651 vaccinia-naïve participants were vaccinated with two doses of MVA-BN LF or FD, 4 weeks apart. The objectives to compare FD terms vaccine-induced immune responses, safety,...
5006 Background: PRO is a PSA-targeted, poxvirus-based cancer vaccine using heterologous prime-boost regimen comprising recombinant vaccinia vector prime followed by 6 booster doses with the fowlpox vector. PROSPECT was designed as confirmatory trial of prior randomized phase 2 (RandPh2) that showed 8.5 months prolongation median OS (25.1 m vs 16.6 Placebo (Pbo)) (Kantoff, JCO 2010; 28:1099) Methods: Double-blind randomization to one following 3 arms: PRO+Pbo (V), PRO+GM-CSF (VG), or Pbo+Pbo...
Abstract Orthopox virus-induced diseases such as smallpox and mpox (also known monkeypox previously) remain a serious public health concern. Modified Vaccinia Ankara Bavarian Nordic (MVA-BN) has been approved in its liquid-frozen (LF) formulation for prevention of the US, Canada EU. A freeze-dried (FD) might confer additional benefits longer shelf life less reliance on cold chain storage transport, thus can better meet potential challenge large quantity vaccine deployment emergency...
ABSTRACT Respiratory syncytial virus (RSV) causes a significant disease burden in older adults. The live recombinant vaccine based on nonreplicating modified vaccinia Ankara (MVA-BN) poxvirus, MVA-BN-RSV, encoding for multiple proteins of RSV subtypes A and B, was assessed efficacy against respiratory caused by RSV. Adults aged ≥ 60 years, with or without underlying chronic conditions, were enrolled randomized 1:1 ratio to receive single dose placebo followed infection during the 2022-2023...
e22161 Background: The ODAC (Oncologic Drug Advisory Committee) Meeting, July 24 th , 2012, on “Evaluation of Radiologic Review Progression-free Survival in Non-hematologic Malignancies” discussed the merits implementing an audit process investigator assessments certain oncology trials with PFS endpoint instead a full Blinded Independent Central (BICR) all cases. discussion centered around two potential methods (Dodd et al., 2008, 2011 and Amit 2011) – their aimed to reduce risk informative...
Abstract While the MVA-BN vaccine has been proven protective against smallpox and monkeypox, long-term immunological persistence or booster effect not described. In this set of clinical studies, participants who had never immunized were randomized to receive, 4 weeks apart: 2 placebo vaccinations (PBO group, N =181); 1 vaccination followed by placebo(1×MVA (2×MVA = 183). addition, with a history received (HSPX + 200). The 1×MVA 2×MVA groups responded increases in neutralizing antibody (nAb)...